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Abstract 
Background: Glycyrrhetinic acid (GA) derivatives had shown not only cytotoxicity but also could trigger apoptosis in 
various human cancer cell lines. Moreover, cinnamic acid (CA) and its phenolic analogues as potent antitumor agents 
were employed in the design of anti-tumor drugs. To further improve the anti-tumor activity of GA and CA derivatives, 
a series of novel compounds were designed and synthesized using GA and CA derivatives fragments.
Results: The result showed that all the novel glycyrrhetinic acid-cinnamoyl (GA–CA) hybrids presented higher 
antitumor activity on the tumor cell lines of HepG2, HT-29, Hela and lower cytotoxicity on three non-tumor cells lines 
MDCK, HY926, H9C2 than the parent compounds (IC50 > 50 μM). It was worth noting that 8a had a superior cytotox-
icity effect on Hela cells (IC50 = 8.54 μM) than on other cancer cell lines (IC50 > 15 μM). And it also indicated that 8a 
showed lower cytotoxicity (IC50 > 27 μM) towards MDCK, HY926 and H9C2 cells than cisplatin (DDP, IC50 < 10 μM). 
Moreover, according to the acute toxicity, it could be indicated that the LD50 of 8a exceeded 3.0 g/kg by oral admin-
istration in mice. The further research using Giemsa, H33342 staining, flow cytometric analysis and caspase-3 assay 
showed that 8a could cause Hela cell damage, nuclei lysis and apoptosis. In addition, the structure–activity relation-
ships of these hybrids were briefly discussed.
Conclusions: Compared with GA, target compounds demonstrated better anti-tumor activity, among which 8a was 
the most active one. What’s more, structure–activity relationship analysis also revealed that hybrids with trans olefinic 
bond group show higher antitumor activity than those without olefinic bond, such as 1a > 1b, 6a > 2b, 8a > 3b, 
9a > 4b. In addition, it was found that the methoxy substituent might enhance selectivity of GA–CA hybrids towards 
regular non-cancerous cells MDCK, HY926 and H9C2, such as 4a, 6a, 7a, 8a. However, there might be less relation-
ship between the cytotoxicity and the quantity, position of methoxy moiety. Hence, it is urgent need to synthesize 
efficient, low toxicity and multi-target anti-tumor compounds based on the structure combination principle.
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Background
In the process of drug discovery and development, natu-
ral products play a highly significant role [1, 2]. A series of 
pentacyclic triterpenoids were proved to have potent anti-
tumor activity [3–6]. Structural modification of bioactive 
natural products according to combination principle was 
an important approach in search for new lead compounds 
[7–9]. Based on this principle, previous studies in our lab-
oratory had already obtained a series of novel antitumor 
compounds with promising cytotoxicity [10–12]. Given 
the potent cytotoxicity and apoptosis-inducing activity of 
the natural pentacyclic triterpenoid GA, it is becoming a 
valuable lead compound in the design of anti-tumor drug 
[13]. It also had been reported that GA possessed selective 
toxicity to varieties of tumor cells [14, 15]. The previous 
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researches showed the introduction of ester-joined groups 
at 3-OH of GA could enhance the antitumor effect [16, 
17]. Meanwhile, CA and its phenolic analogues were also 
employed as the active scaffold in the design of anti-tumor 
drugs for their potent cytotoxicity [13, 18–21]. Moreover, 
CA moiety could induce selective cytotoxicity in develop-
ing anti-tumor agents [21]. To further improve the anti-
tumor effect of GA and CA derivatives and find a series 
of efficient, low toxicity, multi-target GA–CA hybrids, we 
integrated the GA and CA derivatives fragments into one 




All the designed hybrids were synthesized according to 
Scheme  1. The coupling reactions between GA and the 
corresponding CA derivatives were performed using 
dimethylaminopyridine (DMAP) and dicyclohexylcar-
bodiimide (DCC) as the catalyst in anhydrous dichlo-
romethane (DCM), to afford glycyrrhetinic acid hybrids 
1a–9a, as shown in Scheme 1. Subsequently, compounds 
1a, 6a, 8a, 9a were further hydrogenated by Pd/C to 
obtain the target compounds 1b–4b. The structures of all 
target compounds (Tables 1, 2) were determined by 1H-
NMR, 13C-NMR and mass spectrometer (ESI–MS).
Biological activity
Cytotoxicity assay
As shown in Table 3, all the synthesized compounds were 
tested for their cytotoxicity on three tumor cell lines 
(HepG2, HT-29, and Hela) and three non-tumor cell lines 
(MDCK HY926 and H9C2) using the standard MTT 
assay and IC50 values for different cell lines were outlined.
After combination, most of the synthesized com-
pounds showed improved cytotoxicity compared to GA. 
Among them, compound 8a demonstrated better cyto-
toxicity (IC50 = 8.54 μM) against Hela. Structure–activ-
ity relationship analysis among 1a, 6a, 8a, 9a, 1b–4b also 
revealed that compounds with trans olefinic bond group 
seemed to more active than those without olefinic bond, 
such as 1a > 1b, 6a > 2b, 8a > 3b, 9a > 4b. This struc-
ture–activity relationship analysis was in agreement with 
our previous study in designing neuroprotective agents 
[9]. Compared to 1a (IC50 < 25 μM), it was found that the 
methoxy substituent might enhance cytotoxicity selec-
tivity of GA–CA hybrids towards tumor cell lines, such 
as 4a, 6a, 7a, 8a. This was in accordance with the previ-
ous study that dihydroartemisinin-cinnamic acid ester 
hybrids with methoxy moiety displayed highly selective 
cytotoxicity against the human lung carcinoma A549 






















Scheme 1 Reagents and conditions: (i) anhydrous CH2Cl2, DMAP/DCC, 24 h; (ii) THF, Pd/C, H2, 2 h
Table 1 The structures of glycyrrhetinic acid hybrids 1a–9a 
No. R1 R2 R3 R4
1a H H H H
2a H H CH3 H
3a OCH3 H H H
4a H OCH3 H H
5a H H OCH3 H
6a OCH3 OCH3 H H
7a OCH3 H H OCH3
8a OCH3 OCH3 OCH3 H
9a H OCH3 OCH3 OCH3
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hepatic L-02 cells [21]. However, there might be less rela-
tionship between cytotoxicity and the quantity, position 
of methoxy moiety. These findings may provide a new 
framework for the design of new GA hybrids as anti-
tumor drugs.
Cytotoxicity selectivity
Based on the above evidence, 8a showed selective cyto-
toxicity towards Hela cell lines. The different inhibi-
tion activity of 8a for Hela, HY926, MDCK and H9C2 
cells are shown in Fig.  1 detailedly. Taken together, the 
results demonstrated that 8a displayed not only selective 
cytotoxicity on Hela cell lines, but also a concentration-
dependent manner.
From the obtained results, we can see the inhibition 
rate of 8a at 12.5 μM against MDCK, HY926, H9C2 and 
Hela were 38.56, 20.20, 3.56 and 59.20%. Hence, in a cer-
tain degree, compound 8a might have cytotoxicity selec-
tively towards Hela.
Acute toxicity
As the above results showed, 8a had a selective cytotox-
icity against tumor cells. In order to test its safety, the 
acute toxicity of 8a was evaluated by gavage. During the 
2  weeks after oral administration of the maximum tol-
erated dose (3 g/kg), no signs of toxicity or deaths were 
observed.
Giemsa staining on Hela cells
To confirm whether the apoptotic morphological changes 
could be associated with 8a, Hela cells were treated with 
various concentrations of 8a for 72  h and then used 
Giemsa staining. The morphology changes were observed 
and photographed under inverted phase-contrast micro-
scope at a magnification of 200×. With the increase of 
drug concentration, the process of cell loss, nuclei lysis, 
chromatin condensation and cytoplasmic shrinkage were 
aggravated (Fig. 2).
H33342 staining on Hela cells
To confirm whether the characteristic nuclear changes 
could be associated with 8a, Hela cells were treated 
Table 2 The structures of glycyrrhetinic acid hybrids 1b–4b 
No. R1 R2 R3 R4
1b H H H H
2b OCH3 OCH3 H H
3b OCH3 OCH3 OCH3 H
4b H OCH3 OCH3 OCH3
Table 3 Anti-proliferative effects of glycyrrhetinic acid hybrids
a IC50 values were calculated using GraphPad Prism 5.01. Data were shown as mean ± SD (n = 3) from three independent experiments
Compound IC50 (μM)
a
Hela HepG2 HT-29 MDCK HY926 H9C2
1a 23.67 ± 2.98 24.40 ± 1.39 22.34 ± 1.75 22.63 ± 1.38 28.93 ± 1.85 46.13 ± 2.01
2a 14.19 ± 1.10 22.08 ± 1.18 21.72 ± 1.81 37.95 ± 1.81 27.63 ± 1.84 >50
3a 24.56 ± 1.72 31.99 ± 1.90 22.16 ± 2.34 22.93 ± 2.43 >50 >50
4a 17.53 ± 1.52 12.67 ± 1.10 14.88 ± 1.80 22.24 ± 2.56 31.01 ± 1.87 >50
5a 23.38 ± 1.38 31.15 ± 1.34 32.99 ± 1.92 21.67 ± 1.01 >50 36.14 ± 1.92
6a 22.48 ± 2.08 24.36 ± 1.44 24.39 ± 1.76 33.67 ± 1.40 24.99 ± 1.38 >50
7a 28.01 ± 1.63 25.41 ± 1.97 26.41 ± 1.96 >50 45.07 ± 2.25 >50
8a 8.54 ± 1.44 21.47 ± 1.50 15.02 ± 1.26 31.84 ± 2.79 27.73 ± 1.39 >50
9a 30.67 ± 1.89 21.88 ± 1.41 25.52 ± 1.29 27.72 ± 1.08 30.79 ± 1.37 47.43 ± 1.07
1b 26.92 ± 1.74 32.29 ± 1.00 28.63 ± 2.99 33.33 ± 2.98 33.65 ± 3.09 >50
2b 23.13 ± 2.33 33.08 ± 2.09 29.34 ± 2.22 41.30 ± 1.48 >50 45.75 ± 1.80
3b 22.54 ± 2.16 27.31 ± 1.95 26.21 ± 1.24 >30 38.46 ± 2.02 >50
4b 28.69 ± 1.68 22.38 ± 1.29 22.35 ± 1.2 >30 >50 >50
GA >50 >50 >50 >100 >100 >100
DPP 3.76 ± 0.38 4.57 ± 0.85 5.28 ± 0.74 9.97 ± 1.12 5.12 ± 0.71 5.31 ± 0.26
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with various concentrations of 8a for 72  h and then 
used H33342 staining. The morphology changes 
were observed and photographed under inverted 
phase-contrast microscope at a magnification of 200×. 
With the increase of drug concentration, the nuclear 
fragmentation, the cytoplasmic shrinkage, and the shape 
of apoptotic cells became irregular (Fig. 3).
Annexin V‑FITC/propidium iodide (PI) assay
The effects of 8a on apoptosis in Hela cells were fur-
ther determined by flow cytometric analysis. Cells were 
treated with 8a at three concentrations of 5, 10, 20  μM 
and then stained with both annexin V-FITC and PI. The 
flow cytometry observed four quadrant images: the Q1 
area represented necrotic cells, the Q2 area represented 
late apoptotic cells, the Q3 area represented intact cells 
and the Q4 area represented the early apoptotic cells. The 
results were shown in Fig.  4. The apoptosis ratios of 8a 
were found from 15.7% (5 μM) to 27.7% (10 μM) and 60% 
(20  μM) which increased gradually in a concentration 
manner, respectively, while that of the control was 7.5%. 
It was indicated that 8a was able to significantly induce 
Hela cells apoptosis. This was in accordance with previ-
ous reports that GA and CA hybrids could induce cancer 
cell apoptosis [5, 20].


























Fig. 1 The different inhibition activity of 8a for Hela, HY926, MDCK 
and H9C2 cells
Fig. 2 Morphological changes observation of Hela cells by Giemsa staining (×200): a control group without 8a; b 5 μM of 8a; c 10 μM of 8a; d 
20 μM of 8a. The cell morphology was observed and photographed under inverted phase-contrast microscope after Giemsa staining
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Caspase‑3 assay
From the results of flow cytometry analysis, it could be 
clarified that 8a was able to significantly induce Hela cells 
apoptosis. What’s more, caspase-3 plays a crucial role in 
the process of apoptosis induced. The method of measur-
ing the levels of ρ-nitroanilide cleaved from the substrate 
N-Ac-DEVD-ρNA was followed to determine the cas-
pase-3 activity. As shown in Fig. 5, caspase-3 activities in 
Hela cells were enhanced in a concentration-dependent 
manner after the cells were exposed to 8a, from which it 
could be implicated that caspase-3 was activated by 8a to 
promote the apoptosis of the cells.
Conclusions
Studies on synthetic glycyrrhetinic acid derivatives and 
their bioactivities drew considerable attention in the 
past several years. Our experimental findings suggested 
that all GA–CA hybrids showed better cytotoxicity than 
the parent materials in tested cancer cells. Among the 
active compounds, 8a presented a superior cytotoxic-
ity effect on Hela cells (IC50 =  8.54  μM) than on other 
cancer cell lines and exhibited lower cytotoxicity towards 
three non-tumor cells lines (MDCK, HY926, H9C2) than 
DDP. Furthermore, structure–activity relationship analy-
sis revealed that hybrids with trans olefinic bond group 
were more active than those without olefinic bond, and 
we found that the methoxy substituent could enhance 
cytotoxicity selectivity of GA–CA hybrids. In order to 
further confirm our conclusion, we combined Giemsa, 
H33342 staining, flow cytometric analysis and caspase-3 
assay indicated that 8a could induce Hela cells damage, 
nuclei lysis, block intercellular contact and apoptosis. 
From these results, it obviously suggests that synthesis 
compounds based on the structure combination princi-
ple to discover more efficient and low toxicity anti-tumor 
compounds is of great research value.
Methods
Chemistry information
GA was purchased from State Uni-Bio Technology Co., 
Ltd., Baoji, China. Cinnamic acid and its derivatives were 
obtained from Aladdin Bio-Chem Technology Co., Ltd., 
China and Alfa Aesar Chemical Co., Ltd., Tianjin, China. 
The purity of all the materials, including GA, cinnamic 
Fig. 3 Morphological changes observation of Hela cells by H33342 staining (×200): a control group without 8a; b 5 μM of 8a; c 10 μM of 8a; d 
20 μM of 8a. The cell morphology was observed and photographed under inverted phase-contrast microscope after H33342 staining
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acid and its derivatives are more than 98% by commercial 
purchase. Reagents of analytical reagent grade were pro-
vided by Beijing Chemical Plant. All reagents and chemi-
cals were used as received without further purification 
unless specific stated. The aluminum sheets covered sil-
ica gel (Qingdao Haiyang Chemical Co., Qingdao, China) 
were used to monitor the reactions.
The melting points of purified products were obtained 
on an X-5 micro melting- point apparatus (Beijing Tech 
Instrument Co., Ltd., Beijing, China). 1H-NMR and 13C-
NMR assays were recorded on a BRUKER AVANCE 
500 or 400 NMR spectrometer (Fällanden, Switzerland). 
ESI–MS were recorded on a Thermo Scientific TM LTQ 
Orbitrap XL hybrid FTMS instrument (Thermo Tech-
nologies, New York, NY, USA). The final products were 
purified on 200–300 mesh silica gel. Cellular morpholo-
gies were observed using an inverted fluorescence micro-
scope (Olympus IX71, Tokyo, Japan). On the last step 
reaction the yields can be calculated.
General procedure for the preparation of glycyrrhetinic acid–
cinnamic acid hybrids 1a–9a
The corresponding cinnamic acid derivatives (6.0 mmol) 
and DMAP (0.6 mmol) were mixed in 50 mL dry DCM, 
as well as DCC. After dissolution, the glycyrrhetinic acid 
(3.5  mmol) was added. The mixture was stirred under 
nitrogen atmosphere at room temperature for 24  h. 
Afterwards, the solution was washed with brine, dried 
over sodium sulfate, filtered and concentrated. To yield 
pure product, the crude product was purified by flash 
chromatography (dichloromethane: methanol = 200:1).
Cinnamoyl-3β-hydroxy-11-oxoolean-12-en-30-oic acid 
(1a). White solid, yield: 45.0%, m.p.: 315.2–318.8 °C. 1H-
NMR (500  MHz, CDCl3) (ppm): 0.85, 0.93, 0.97, 1.15, 
1.20, 1.24, 1.39 (s, each, 3H, 7× –CH3), 4.67 (m, 1H), 
5.73 (s, 1H, =CH–), 6.45 (d, J  =  16.0  Hz, 1H, –CH=), 
7.35–7.40 (m, 3H, Ar–H), 7.53–7.54 (m, 2H, Ar–H), 7.67 
(d, J  =  16.0  Hz, 1H, –CH=), 1.00–3.00 (22H, methyl- 
and methylene- of triterpenoid structure). 13C-NMR 
Fig. 4 Apoptosis analysis by FCM using AnnexinV-FITC/PI staining on the Hela cells treated by 8a; a control group without 8a; b 5 μM of 8a; c 
10 μM of 8a; d 20 μM of 8a
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(125 MHz, CDCl3) (ppm): 16.6, 17.0, 17.5, 18.8, 23.5, 23.8, 
26.6, 26.6, 28.3, 28.6, 28.7, 31.1, 32.0, 32.9, 37.1, 37.9, 38.5, 
39.0, 41.0, 43.4, 43.9, 45.6, 48.4, 55.2, 61.9, 80.8, 119.0, 
128.2, 128.6, 129.0, 130.3, 134.7, 144.5, 167.0, 169.6, 181.6 
(–COOH), 200.5 (–C=O). MS (ESI) m/z: 599 [M-H]−, 
calcd. for C39H52O5 600.
(4-Methyl) cinnamoyl-3β-hydroxy-11-oxoolean-12-en-
30-oic acid (2a). White solid, yield: 47.3%, m.p.: 316.6–
318.1 °C. 1H-NMR (500 MHz, CDCl3) (ppm): 0.84, 0.92, 
0.96, 1.14, 1.19, 1.23, 1.38 (s, each, 3H, 7× –CH3), 2.37 
(s, 3H, –CH3), 4.66 (m, 1H), 5.72 (s, 1H, =CH–), 6.40 (d, 
J = 16.0 Hz, 1H, –CH=), 7.18 (d, J = 8.0 Hz, 2H, Ar–H), 
7.43 (d, J = 8.0 Hz, 2H, Ar–H), 7.64 (d, J = 16.0 Hz, 1H, 
–CH=), 1.00–3.00 (22H, methyl- and methylene- of trit-
erpenoid structure). 13C-NMR (125 MHz, CDCl3) (ppm): 
16.6, 17.0, 17.5, 18.8, 21.6, 23.5, 23.8, 26.5, 26.6, 28.2, 28.6, 
28.7, 31.0, 32.0, 32.9, 37.1, 37.9, 38.4, 38.9, 41.0, 43.4, 
43.9, 45.6, 48.4, 55.2, 61.9, 80.7, 117.8, 128.2, 128.6, 129.7, 
131.9, 140.7, 144.5, 167.2, 169.6, 181.7 (–COOH), 200.5 
(–C=O). MS (ESI) m/z: 613 [M-H]−, calcd. for C40H54O5 
614.
(2-Methoxy) cinnamoyl-3β-hydroxy-11-oxoolean-12-en- 
30-oic acid (3a). White solid, yield: 45.7%, m.p.: 317.0–
319.2  °C. 1H-NMR (500 MHz, CDCl3) (ppm): 0.84, 0.92, 
0.96, 1.14, 1.19, 1.23, 1.38 (s, each, 3H, 7× –CH3), 3.88 (s, 
3H, –OCH3), 4.66 (m, 1H), 5.72 (s, 1H, =CH–), 6.52 (d, 
J = 16.0 Hz, 1H, –CH=), 6.91 (d, J = 8.0 Hz, 1H, Ar–H), 
6.95 (t, J = 7.5 Hz, 1H, Ar–H), 7.35 (m, 1H, Ar–H), 7.51 
(m, 1H, Ar–H), 7.98 (d, J =  16.0 Hz, 1H, –CH=), 1.00–
3.00 (22H, methyl- and methylene- of triterpenoid struc-
ture). 13C-NMR (125  MHz, CDCl3) (ppm): 16.6, 17.0, 
17.5, 18.8, 23.5, 23.8, 26.5, 26.6, 28.2, 28.6, 28.7, 31.0, 32.0, 
32.8, 37.1, 37.8, 38.4, 38.9, 40.9, 43.3, 43.9, 45.6, 48.4, 55.1, 
55.6 (–OCH3), 61.8, 80.5, 111.2, 119.4, 120.8, 123.6, 128.5, 
129.0, 131.5, 139.9, 158.4, 167.5, 169.7, 181.7 (–COOH), 
200.6 (–C=O). MS (ESI) m/z: 629 [M-H]−, calcd. for 
C40H54O6 630.
(3-Methoxy) cinnamoyl-3β-hydroxy-11-oxoolean-12-en- 
30-oic acid (4a). White solid, yield: 65.5%, m.p.: 316.8–
319.1  °C, 1H-NMR (400 MHz, CDCl3) (ppm): 0.84, 0.93, 
0.97, 1.15, 1.20, 1.24, 1.39 (s, each, 3H, 7× –CH3), 3.84 
(s, 3H, –OCH3), 4.67 (m, 1H), 5.72 (s, 1H, =CH–), 6.43 
(d, J  =  16.0  Hz, 1H, –CH=), 6.93 (dd, J  =  8.0, 2.0  Hz, 
1H, Ar–H), 7.05 (s, 1H, Ar–H), 7.13 (d, J =  8.0  Hz, 1H, 
Ar–H), 7.28–7.32 (m, 1H, Ar–H), 7.63 (d, J = 16.0 Hz, 1H, 
–CH=), 1.00–3.00 (22H, methyl- and methylene- of trit-
erpenoid structure). 13C-NMR (100 MHz, CDCl3) (ppm): 
16.6, 17.0, 17.6, 18.9, 23.5, 23.9, 26.6, 26.7, 28.3, 28.6, 28.7, 
31.1, 32.0, 32.9, 37.2, 37.9, 38.5, 39.0, 41.1, 43.4, 44.0, 45.6, 
48.4, 55.2, 55.5 (–OCH3), 61.9, 80.9, 113.0, 116.3, 119.3, 
120.9, 128.7, 130.0, 136.1, 144.4, 160.1, 166.9, 169.5, 181.4 
(–COOH), 200.4 (–C=O). MS (ESI) m/z: 629 [M-H]−, 
calcd. for C40H54O6 630.
(4-Methoxy) cinnamoyl-3β-hydroxy-11-oxoolean-12-en- 
30-oic acid (5a). White solid, yield: 49.4%, m.p.: 316.9–
319.1  °C. 1H-NMR (500 MHz, CDCl3) (ppm): 0.84, 0.92, 
0.95, 1.14, 1.19, 1.23, 1.38 (s, each, 3H, 7× –CH3), 3.83 (s, 
3H, –OCH3), 4.65 (m, 1H), 5.72 (s, 1H, =CH–), 6.32 (d, 
J = 16.0 Hz, 1H, –CH=), 6.90 (d, J = 8.5 Hz, 2H, Ar–H), 
7.48 (d, J = 8.5 Hz, 2H, Ar–H), 7.62 (d, J = 16.0 Hz, 1H, 
–CH=), 1.00–3.00 (22H, methyl- and methylene- of trit-
erpenoid structure). 13C-NMR (125 MHz, CDCl3) (ppm): 
16.6, 17.0, 17.5, 18.8, 23.5, 23.8, 26.5, 26.6, 28.2, 28.6, 28.7, 
31.0, 32.0, 32.8, 37.1, 37.8, 38.4, 38.9, 41.0, 43.3, 43.9, 45.6, 
48.4, 55.2, 55.6 (–OCH3), 61.8, 80.5, 114.4, 116.4, 127.4, 
128.6, 129.8, 144.1, 161.4, 167.3, 170.0, 181.6 (–COOH), 
200.6 (–C=O). MS (ESI) m/z: 631 [M +  H]+, calcd. for 
C40H54O6 630.
(2,3-Dimethoxy) cinnamoyl-3β-hydroxy-11-oxoolean-
12-en-30-oic acid (6a). White solid, yield: 53.4%, m.p.: 
315.1–318.4 °C. 1H-NMR (400 MHz, CDCl3) (ppm): 0.84, 
0.93, 0.96, 1.14, 1.20, 1.24, 1.39 (s, each, 3H, 7× –CH3), 
3.86 (s, 3H, –OCH3), 3.88 (s, 3H, –OCH3), 4.66 (m, 1H), 
5.72 (s, 1H, =CH–), 6.47 (d, J  =  16.2  Hz, 1H, –CH=), 
6.93 (dd, J = 8.0, 1.2 Hz, 1H, Ar–H), 7.05 (t, J = 8.0 Hz, 
1H, Ar–H), 7.17 (dd, J  =  8.0, 1.2  Hz, 1H, Ar–H), 8.00 
(d, J  =  16.0  Hz, 1H, –CH=), 1.00–3.00 (22H, methyl- 
and methylene- of triterpenoid structure). 13C-NMR 
(100  MHz, CDCl3) (ppm): 16.6, 17.0, 17.6, 18.9, 23.6, 
23.9, 26.6, 26.7, 28.3, 28.6, 28.7, 31.1, 32.0, 32.9, 37.2, 37.9, 
38.5, 39.0, 41.1, 43.4, 43.9, 45.7, 48.4, 55.3, 56.1 (–OCH3), 
Fig. 5 Caspase-3 activity of 8a on Hela cells. Values of caspase-3 
activity are reported as mean ± SD (n = 3). *Compared with control 
group, P < 0.05
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61.5 (–OCH3), 61.9, 80.8, 114.0, 119.4, 120.2, 124.3, 128.7, 
128.9, 139.2, 148.6, 153.3, 167.1, 169.5, 181.3 (–COOH), 
200.5 (–C=O). MS (ESI) m/z: 659 [M-H]−, calcd. for 
C41H56O7 660.
(2,5-Dimethoxy) cinnamoyl-3β-hydroxy-11-oxoolean-12- 
en-30-oic acid (7a). White solid, yield: 57.1%, m.p.: 316.4–
319.1  °C. 1H-NMR (400  MHz, CDCl3) (ppm): 0.85, 0.94, 
0.98, 1.16, 1.21, 1.25, 1.40 (s, each, 3H, 7× –CH3), 3.80 (s, 
3H, –OCH3), 3.85 (s, 3H, –OCH3), 4.68 (m, 1H), 5.72 (s, 
1H, =CH–), 6.49 (d, J =  16.1  Hz, 1H, –CH=), 6.90 (m, 
1H, Ar–H), 6.85 (brs, 1H, Ar–H), 7.06 (m, 1H, Ar–H), 
7.96 (d, J = 16.1 Hz, 1H, –CH=), 1.00–3.00 (22H, methyl- 
and methylene- of triterpenoid structure). 13C-NMR 
(100 MHz, CDCl3) (ppm): 16.6, 17.0, 17.6, 18.9, 23.5, 23.9, 
26.6, 26.7, 28.3, 28.6, 28.7, 31.1, 32.1, 32.9, 37.2, 37.9, 38.5, 
39.0, 41.1, 43.4, 43.9, 45.7, 48.4, 55.3, 56.0 (–OCH3), 56.3 (–
OCH3), 61.9, 80.7, 112.7, 113.6, 117.2, 119.6, 124.4, 128.7, 
139.7, 153.0, 153.7, 167.3, 169.4, 181.0 (–COOH), 200.4 
(–C=O). MS (ESI) m/z: 659 [M-H]−, calcd. for C41H56O7 
660.
(2,3,4-Trimethoxy) cinnamoyl-3β-hydroxy-11-oxoolean-
12-en-30-oic acid (8a). White solid, yield: 66.7%, m.p.: 
315.1–317.9  °C. 1H-NMR (400  MHz, CDCl3) (ppm): 
0.84, 0.93, 0.96, 1.15, 1.20, 1.24, 1.39 (s, each, 3H, 7× –
CH3), 3.87 (s, 3H, –OCH3), 3.89 (s, 3H, –OCH3), 3.92 (s, 
3H, –OCH3), 4.66 (m, 1H), 5.72 (s, 1H, =CH–), 6.40 (d, 
J = 16.0 Hz, 1H, –CH=), 6.69 (d, J = 8.8 Hz, 1H, Ar–H), 
7.28 (d, J = 8.8 Hz, 1H, Ar–H), 7.88 (d, J = 16.0 Hz, 1H, 
–CH=), 1.00–3.00 (22H, methyl- and methylene- of trit-
erpenoid structure). 13C-NMR (100 MHz, CDCl3) (ppm): 
16.6, 17.0, 17.6, 18.9, 23.5, 23.9, 26.6, 26.7, 28.3, 28.6, 28.7, 
31.1, 32.0, 32.9, 37.2, 37.9, 38.5, 39.0, 41.1, 43.4, 44.0, 45.7, 
48.4, 55.3, 56.2 (–OCH3), 61.0 (–OCH3), 61.6 (–OCH3), 
61.9, 80.6, 107.8, 117.8, 121.8, 123.2, 128.7, 139.4, 142.6, 
153.4, 155.6, 167.5, 169.4, 181.5 (–COOH), 200.4 (–C=O). 
MS (ESI) m/z: 689 [M-H]−, calcd. for C42H58O8 690.
(3,4,5-Trimethoxy) cinnamoyl-3β-hydroxy-11-oxoolean-
12-en-30-oic acid (9a). White solid, yield: 55.2%, m.p.: 
315.3–317.7  °C. 1H-NMR (400  MHz, CDCl3) (ppm): 
0.84, 0.93, 0.97, 1.15, 1.20, 1.24, 1.39 (s, each, 3H, 7× –
CH3), 3.88 (s, 3H, –OCH3), 3.89 (s, 6H, 2× –OCH3), 
4.68 (m, 1H), 5.72 (s, 1H, =CH–), 6.35 (d, J =  16.0  Hz, 
1H, –CH=), 6.75 (s, 2H, Ar–H), 7.58 (d, J = 16.0 Hz, 1H, 
–CH=), 1.00–3.00 (22H, methyl- and methylene- of trit-
erpenoid structure). 13C-NMR (100 MHz, CDCl3) (ppm): 
16.6, 17.0, 17.5, 18.8, 23.5, 23.9, 26.5, 26.6, 28.3, 28.6, 28.7, 
31.1, 32.0, 32.9, 37.1, 37.9, 38.5, 39.0, 41.0, 43.4, 43.9, 45.6, 
48.4, 55.2, 56.3 (–OCH3), 61.1 (–OCH3), 61.9, 80.8, 105.3, 
118.2, 128.6, 130.2, 140.1, 144.5, 153.6, 167.0, 169.7, 181.5 
(–COOH), 200.5 (–C=O). MS (ESI) m/z: 689 [M-H]−, 
calcd. for C42H58O8 690.
General procedure for the preparation of glycyrrhetinic acid–
cinnamic acid hybrids 1b–4b
Compounds 1a, 6a, 8a, 9a (2  mmol) were hydrogen-
ated by Pd/C (10%; 50.0 mg) in 30 mL THF. The mixture 
was stirred at room temperature for 2  h and filtered to 
remove Pd/C. The filtrate was concentrated in vacuum.
Phenylpropanoyl-3β-hydroxy-11-oxoolean-12-en-
30-oic acid (1b). White solid, yield: 94.0%, m.p.: 313.6–
316.5 °C. 1H-NMR (400 MHz, CDCl3) (ppm): 0.80, 0.84, 
0.84, 1.13, 1.15, 1.23, 1.27 (s, each, 3H, 7× –CH3), 2.64 
(m, 2H, –CH2), 2.96 (m, 2H, –CH2), 4.52 (m, 1H), 5.71 (s, 
1H, =CH–), 7.17–7.22 (m, 3H, Ar–H), 7.27–7.30 (m, 2H, 
Ar–H), 1.00–3.00 (22H, methyl- and methylene- of trit-
erpenoid structure). 13C-NMR (100 MHz, CDCl3) (ppm): 
16.5, 16.7, 17.5, 18.8, 23.5, 23.7, 26.6, 26.6, 28.1, 28.6, 28.7, 
31.1, 31.3, 32.0, 32.9, 36.4, 37.1, 37.9, 38.2, 38.9, 41.0, 43.4, 
43.9, 45.6, 48.4, 55.2, 61.9, 80.9, 126.4, 128.4, 128.6, 140.7, 
169.6, 172.9, 181.7 (–COOH), 200.5 (–C=O). MS (ESI) 
m/z: 601 [M-H]−, calcd. for C39H54O5 602.
(2,3-Dimethoxy) phenylpropanoyl-3β-hydroxy-11-oxoo­
lean-12-en-30-oic acid (2b). White solid, yield: 97.3%, 
m.p.: 317.4–319.1  °C. 1H-NMR (400  MHz, CDCl3) 
(ppm): 0.83, 0.83, 0.85, 1.13, 1.15, 1.23, 1.37 (s, each, 3H, 
7× –CH3), 2.59–2.64 (m, 2H, –CH2), 2.93–2.98 (m, 2H, 
–CH2), 3.84 (s, 3H, –OCH3), 3.85 (s, 3H, –OCH3), 4.51 
(m, 1H), 5.71 (s, 1H, =CH–), 6.80–6.77 (m, 2H, Ar–H), 
6.97 (t, J = 8.0 Hz, 1H, Ar–H), 1.00–3.00 (22H, methyl- 
and methylene- of triterpenoid structure). 13C-NMR 
(100  MHz, CDCl3) (ppm): 16.5, 16.8, 17.5, 18.8, 23.5, 
23.7, 25.7, 26.6, 26.6, 28.2, 28.6, 28.7, 31.1, 32.0, 32.9, 35.4, 
37.1, 37.9, 38.2, 39.0, 41.0, 43.4, 43.9, 45.6, 48.4, 55.2, 55.9 
(–OCH3), 60.7 (–OCH3), 61.8, 80.7, 110.9, 121.9, 124.0, 
128.6, 134.5, 147.4, 152.9, 169.6, 173.1, 181.5 (–COOH), 
200.5 (–C=O). MS (ESI) m/z: 661 [M-H]−, calcd. for 
C41H58O7 662.
(2,3,4-Trimethoxy) phenylpropanoyl-3β-hydroxy-11-oxo­
olean-12-en-30-oic acid (3b). White solid, yield: 95.5%, 
m.p.: 316.3–319.1 °C. 1H-NMR (400 MHz, CDCl3) (ppm): 
0.81, 0.83, 0.84, 1.12, 1.15, 1.22, 1.37 (s, each, 3H, 7× –
CH3), 2.58 (t, J = 8.0 Hz, 2H, –CH2), 2.88 (t, J = 8.0 Hz, 
2H, –CH2), 3.83 (s, 3H, –OCH3), 3.85 (s, 3H, –OCH3), 
3.89 (s, 3H, –OCH3), 4.50 (m, 1H), 5.71 (s, 1H, =CH–), 
6.57 (d, J =  8.8  Hz, 1H, Ar–H), 6.83 (d, J =  8.8  Hz, 1H, 
Ar–H), 1.00–3.00 (22H, methyl- and methylene- of trit-
erpenoid structure). 13C-NMR (100 MHz, CDCl3) (ppm): 
16.5, 16.8, 17.5, 18.8, 23.5, 23.7, 25.7, 26.5, 26.6, 28.1, 28.6, 
28.7, 31.0, 32.0, 32.8, 35.6, 37.0, 37.8, 38.2, 38.9, 41.0, 43.3, 
43.9, 45.6, 48.4, 55.1, 56.1 (–OCH3), 60.8 (–OCH3), 61.0 (–
OCH3), 61.8, 80.6, 107.2, 123.9, 126.6, 128.5, 142.4, 152.0, 
152.5, 169.6, 173.2, 182.0 (–COOH), 200.5 (–C=O). MS 
(ESI) m/z: 691 [M-H]−, calcd. for C42H60O8 692.
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(3,4,5-Trimethoxy) phenylpropanoyl-3β-hydroxy-11-oxo­
olean-12-en-30-oic acid (4b). White solid, yield: 95.5%, 
m.p.: 315.1–319.7 °C. 1H-NMR (400 MHz, CDCl3) (ppm): 
0.79, 0.83, 0.85, 1.12, 1.15, 1.23, 1.37 (s, each, 3H, 7× –
CH3), 2.63 (t, J = 8.0 Hz, 2H, –CH2), 2.90 (t, J = 8.0 Hz, 
2H, –CH2), 3.81 (s, 3H, –OCH3), 3.84 (s, 6H, 2× –
OCH3), 4.53 (m, 1H), 5.71 (s, 1H, =CH–), 6.42 (s, 2H, 
Ar–H), 1.00–3.00 (22H, methyl- and methylene- of trit-
erpenoid structure). 13C-NMR (100 MHz, CDCl3) (ppm): 
16.5, 16.9, 17.5, 18.8, 23.5, 23.8, 26.5, 26.6, 28.1, 28.6, 28.7, 
31.1, 31.6, 32.0, 32.8, 36.5, 37.1, 37.9, 38.2, 38.9, 41.0, 43.4, 
43.9, 45.6, 48.4, 55.2, 56.2 (–OCH3), 61.0 (–OCH3), 61.8, 
80.9, 105.4, 128.6, 136.5, 136.6, 153.3, 169.6, 172.8, 181.6 
(–COOH), 200.5 (–C=O). MS (ESI) m/z: 691 [M-H]−, 
calcd. for C42H60O8 692.
Bio-evaluation methods
Cell culture
HepG2 (human hepatocellular carcinoma), Hela (human 
cervical cancer), HT-29 (human colon carcinoma), 
MDCK (Madin–Darby canine kidney), H9C2 (rat myo-
cardial cells) and HY926 were purchased from the Chi-
nese Academy of Medical Sciences and Peking Union 
Medical College. All of these cell lines were maintained in 
RPMI-1640 (DMEM) supplemented with 10% (v/v) fetal 
bovine serum (FBS) and 1% (v/v) penicillin/streptomy-
cin (Thermo Technologies, New York, NY, USA) under a 
humidified atmosphere containing 5% CO2 at 37  °C. To 
provide stock solutions which were used to prepare vari-
ous concentrations of treatment media, GA and hybrids 
were added a volume of DMSO.
Cytotoxicity evaluation
The cytotoxicity of these compounds was evaluated on 
three human cancer cell lines (HepG2, HT-29, Hela) and 
three non-tumor cells lines (MDCK, HY926, H9C2) and 
MTT assay was performed to detect the cell prolifera-
tion. Simply, exponentially growing cells were cultured 
in 96-well plates (3 × 103 cells/well). And the plates were 
placed in a humidified atmosphere for 72 h at 37 °C with 
5% CO2. After added MTT solution (5 mg/mL) 20 μL to 
each well, the plate was incubated for a further 4 h. Then 
the cell supernatant was removed and 150 μL DMSO was 
added. Finally, the absorbance was determined at wave-
length of 490  nm with the ELISA. Wells without drugs 
were used to be blanks. The IC50 values were calculated 
using Logit-method. The following Eq. (1) was proposed 









Forty healthy Kunming mice (weight 18–22  g) of both 
sexes were purchased from Beijing Vital River Labora-
tory Animal Technology Company Limited (Beijing, 
China). The mice were divided into two groups matched 
the same weight and size, along with the standard in our 
previous studies [22]. In briefly, 20 mice were selected 
for blank control group, and the other 20 mice were for 
the treated group. All experiments followed the guide-
lines of “Regulation for the Administration of Affairs 
Concerning Experimental Animals” (State Council of 
China, 1988). All animals were placed in cages, fed with 
standard rodent chow and water ad libitum under a 12-h 
light–dark cycle. Before the experiments, the mice were 
deprived of food for 12 h but provided water freely. Then 
the treated group of both sexes were administered a sin-
gle dose of 8a (0.3 mL/10 g) via gavage twice a day, which 
was prepared in advance in bean oil solution with the 
maximum suspended dose (50 mg/mL). The total admin-
istration of 8a was 3 g/kg during 8 h. And the blank con-
trol group were given bean oil by oral administration 
only. The mice’s general behavior was continuously noted 
in the first hour, intermittently observed in the next 4 h, 
and thereafter over a period of 24 h. Observations of the 
signs for toxicity and deaths were last for 14  days. The 
mortality response and behavior of toxic effects of mice 
were recorded.
Giemsa staining on Hela cells
Hela cells were seeded in 12-well plates (5 ×  103 cells/
well), and then they were cultured for 24 h at 37 °C with 
5% CO2. After that each group was added 8a, making the 
final concentration of 0, 5, 10, 20 μM respectively. After 
72 h, the cell supernatant was removed and the cells were 
cleaned with PBS twice, then kept in PBS/ethanol (1:1) 
for 2 min and fixed with cold ethanol for 10 min. After 
discarding ethanol, the cells were stained with Giemsa 
(Giemsa, Molecular Probes/Invitrogen Life Technolo-
gies, Carlsbad, CA, USA) stained for 5 min and washed 
with water. In the end, the cells were observed and pho-
tographed under inverted phase-contrast microscope at a 
magnification of 200×.
H33342 staining on Hela cells
H33342 staining was used to confirm whether the char-
acteristic nuclear changes were associated with 8a in this 
assay. Hela cells were cultured in 12-well plates (5 × 104 
cells/well), which were placed in a humidified atmos-
phere for 24  h at 37  °C with 5% CO2. And then each 
group was added 8a, making the final concentration of 0, 
5, 10, 20 μM respectively. After 72 h, cell culture medium 
was discarded and the cells were washed twice with 
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PBS. H33342 staining was then performed for 2 min and 
washed with water. In the end, the cells were observed 
and photographed under inverted phase-contrast micro-
scope at a magnification of 200×.
Annexin V‑FITC/propidium iodide (PI) assay
Hela cells were seeded in 12-well plates (5 ×  104 cells/
well), which were placed in a humidified atmosphere 
for 24 h at 37 °C with 5% CO2. After treated with differ-
ent concentrations of 8a (5, 10, 20 μM) for 72 h, all cells 
were collected respectively with the right amount of 
trypsin (without EDTA) digestion. After added 1 mL cold 
PBS, the cells were gently suspended and centrifuged at 
1000 rpm for 5 min. The harvested cells were suspended 
in 200 μL binding buffer which contained 10 μL Annexin 
V-FITC and PI. After avoided light reaction for 15 min, 
the cells were analyzed with a flow cytometry (BD, USA).
Caspase‑3 assay
Hela cells were seeded in dishes at a density of 5 × 105 
cell per dish and the dishes were kept at 37  °C with 5% 
CO2 for 24 h. On the next day, various concentration of 
8a (0, 5, 10, 20 μM) were added to the cells and cultured 
for 48 h. Pre-cooled PBS were added twice to wash the 
cells. After removal of the medium, ice-cold cell lysis 
buffer was added, and the cells were further incubated 
in an ice bath for 15 min, which contribute to the pro-
tein acquisition. The caspase-3 activity kit (Beyotime 
Institute of Biotechnology, Beijing, China) was used to 
determine the activity of caspase-3. A total of 50 μL cell 
lysates, 40 μL reaction buffer and 10 μL caspase-3 sub-
strate (Ac-DEVDpNA) (2  mM) were added to 96-well 
plates. After 30  min of incubation, absorbance was 
measured at 405 nm, and samples were quantified with 
ELISA.
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